US FDA's Stellar Drug Review Performance Is Straining Workforce
This article was originally published in SRA
The US Food and Drug Administration's stellar performance in meeting review goals comes at a cost of "a lot of strain behind the scenes," Office of New Drugs director John Jenkins told the FDA/CMS Summit in Washington, DC, on Dec. 14 - an audience that included stakeholders involved in negotiating the next round of the Prescription Drug User Fee Act (PDUFA VI).
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.